Answer
Yes, potentially fatal interstitial lung disease has been reported with Pazopanib, and patients should be monitored for pulmonary symptoms and Pazopanib discontinued if interstitial lung disease or pneumonitis develops.
Sources for this answer
- Pazopanib 200 mg film-coated tabletsDr. Reddy's Laboratories (UK) Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 1Document updated
Sources checked